These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 7648773)

  • 21. The use of selegiline in Alzheimer's patients with behavior problems.
    Goad DL; Davis CM; Liem P; Fuselier CC; McCormack JR; Olsen KM
    J Clin Psychiatry; 1991 Aug; 52(8):342-5. PubMed ID: 1907964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do patients diagnosed with Alzheimer's disease benefit from a psycho-educational programme for family caregivers? A randomised controlled study.
    de Rotrou J; Cantegreil I; Faucounau V; Wenisch E; Chausson C; Jegou D; Grabar S; Rigaud AS
    Int J Geriatr Psychiatry; 2011 Aug; 26(8):833-42. PubMed ID: 20922772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of phosphatidylserine in Alzheimer's disease.
    Crook T; Petrie W; Wells C; Massari DC
    Psychopharmacol Bull; 1992; 28(1):61-6. PubMed ID: 1609044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences between physician and caregiver evaluations in Alzheimer's disease.
    Sinforiani E; Pasotti C; Chiapella L; Malinverni P; Zucchella C
    Funct Neurol; 2010; 25(4):205-9. PubMed ID: 21388581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease.
    Pomara N; Deptula D; Singh R
    Psychopharmacol Bull; 1991; 27(3):301-7. PubMed ID: 1775603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of efficacy of hydergine in patients with Alzheimer's disease.
    Thompson TL; Filley CM; Mitchell WD; Culig KM; LoVerde M; Byyny RL
    N Engl J Med; 1990 Aug; 323(7):445-8. PubMed ID: 2082953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Family stigma and caregiver burden in Alzheimer's disease.
    Werner P; Mittelman MS; Goldstein D; Heinik J
    Gerontologist; 2012 Feb; 52(1):89-97. PubMed ID: 22048807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-caregiver concordance in symptom assessment and improvement in outcomes for patients undergoing cancer chemotherapy.
    Silveira MJ; Given CW; Given B; Rosland AM; Piette JD
    Chronic Illn; 2010 Mar; 6(1):46-56. PubMed ID: 20308350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The mental stress of the accompaniment in Alzheimer's disease].
    Caron R; Caron L
    Encephale; 2011 Dec; 37(6):439-47. PubMed ID: 22137216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease.
    Zemlan FP; Keys M; Richter RW; Strub RL
    Life Sci; 1996; 58(21):1823-32. PubMed ID: 8637408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Noradrenergic intervention in Alzheimer's disease.
    Crook T; Wilner E; Rothwell A; Winterling D; McEntee W
    Psychopharmacol Bull; 1992; 28(1):67-70. PubMed ID: 1609045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracerebroventricular cholinergic drug administration in Alzheimer's disease: preliminary results of a double-blind study.
    Harbaugh RE
    J Neural Transm Suppl; 1987; 24():271-7. PubMed ID: 2890709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.
    Raskind MA; Sadowsky CH; Sigmund WR; Beitler PJ; Auster SB
    Arch Neurol; 1997 Jul; 54(7):836-40. PubMed ID: 9236571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter trial of naloxone in Alzheimer's disease.
    Henderson VW; Roberts E; Wimer C; Bardolph EL; Chui HC; Damasio AR; Eslinger PJ; Folstein MF; Schneider LS; Teng EL
    Ann Neurol; 1989 Apr; 25(4):404-6. PubMed ID: 2653175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.
    Padala PR; Padala KP; Lensing SY; Ramirez D; Monga V; Bopp MM; Roberson PK; Dennis RA; Petty F; Sullivan DH; Burke WJ
    Am J Psychiatry; 2018 Feb; 175(2):159-168. PubMed ID: 28945120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Influence of acupuncture on isoprostane in patients with Alzheimer's disease].
    Zhu H; Dong KL; Wu Y; Zhang T; Li RM; Dai SS; Wang HL
    Zhongguo Zhen Jiu; 2010 Jan; 30(1):18-21. PubMed ID: 20353108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. Metrifonate in Alzheimer's Disease Trial.
    Shikiar R; Shakespeare A; Sagnier PP; Wilkinson D; McKeith I; Dartigues JF; Dubois B
    J Am Geriatr Soc; 2000 Mar; 48(3):268-74. PubMed ID: 10733052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low dose oral haloperidol and blood levels in Alzheimer's disease: a preliminary study.
    Devanand DP; Cooper T; Sackeim HA; Taurke E; Mayeux R
    Psychopharmacol Bull; 1992; 28(2):169-73. PubMed ID: 1513920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.